Herein, we present evidence for the potential contributions of B7-H4 to tumoral immune escape in ccRCC, which indicates that B7-H4 may be used as a new biological molecular marker for select treatment options in patients with ccRCC. The gene discussed is VTCN1; the disease is nonpapillary renal cell carcinoma.